Revvity Execs to Outline Strategy at Three Key Healthcare Conferences
Event summary
- Revvity CFO Max Krakowiak to present at Raymond James conference on March 2, 2026
- CEO Prahlad Singh scheduled for TD Cowen and Barclays healthcare conferences
- Company to discuss strategic priorities during fireside chats
- Revvity reported $2.9B revenue in 2025 with 11,000 employees
- Webcasts and replays available on Investor Relations page
The big picture
Revvity's participation in three major investor conferences suggests a push to reinforce its position as a health science innovator. With $2.9B in revenue and operations across 160 countries, the company appears focused on communicating its strategic priorities amid an evolving healthcare technology landscape. The back-to-back appearances by CEO Prahlad Singh and CFO Max Krakowiak indicate a coordinated effort to address investor concerns about growth and market differentiation.
What we're watching
- Strategic Clarity
- How Revvity will articulate its path to growth amid healthcare sector consolidation
- Execution Risk
- Whether the company can deliver on its $2.9B revenue base while expanding specialized healthcare solutions
- Market Positioning
- The pace at which Revvity can differentiate itself in translational multi-omics and biomarker identification